Preclinical evaluation of an O6-methylguanine-DNA methyltransferase-siRNA/liposome complex administered by convection-enhanced delivery to rat and porcine brains

American Journal of Translational Research

Volumn 6, Issue 2, 2014, Pages 169-178

  Tsujiuchi, Takashi ^a   Natsume, Atsushi ^a   Motomura, Kazuya ^a   Kondo, Goro ^a   Ranjit, Melissa ^a   Hachisu, Rei ^b   Sugimura, Itsuro ^c   Tomita, Shinpei ^c   Takehara, Isao ^c   Woolley, Max ^d   Barua, Neil U ^e   Gill, Steven S ^e   Bienemann, Alison S ^e   Yamashita, Yoriko ^a   Toyokuni, Shinya ^a   Wakabayashi, Toshihiko ^a  

^a NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Custom Biotechnology Service Group   (Japan)

^c New Drug Development Research Center Inc   (Japan)

^d RENISHAW PLC   (United Kingdom)

^e UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cationic liposome; Convection enhaced delivery; Glioblastoma; MGMT; Si RNA

Indexed keywords

GADOLINIUM; LIPOSOME; LIPOTRUST EX OLIGO; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SMALL INTERFERING RNA; TEMOZOLOMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD CELL COUNT; BRAIN; BRAIN DYSFUNCTION; CONTROLLED STUDY; CORPUS CALLOSUM; DRUG DELIVERY SYSTEM; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENETIC TRANSFECTION; GLIOBLASTOMA; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RAT; SWINE;

EID: 84892987104     PISSN: None     EISSN: 19438141     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E and Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 2005; 352: 987-996.
2. Day RS 3rd, Ziolkowski CH, Scudiero DA, Meyer SA, Lubiniecki AS, Girardi AJ, Galloway SM and Bynum GD. Defective repair of alkylated DNA by human tumour and SV40-transformed human cell strains. Nature 1980; 288: 724-727.
3. Gerson SL. MGMT: its role in cancer aetiology and cancer therapeutics. Nat Rev Cancer 2004; 4: 296-307.
4. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, Huang W and Parker R. In vitro drug response and molecular markers associated with drug resistance in malignant gliomas. Clin Cancer Res 2006; 12: 4523-4532.
5. Ma J, Murphy M, O'Dwyer PJ, Berman E, Reed K and Gallo JM. Biochemical changes associated with a multidrug-resistant phenotype of a human glioma cell line with temozolomide-acquired resistance. Biochem Pharmacol 2002; 63: 1219-1228.
6. Hermisson M, Klumpp A, Wick W, Wischhusen J, Nagel G, Roos W, Kaina B and Weller M. O6-methylguanine DNA methyltransferase and p53 status predict temozolomide sensitivity in human malignant glioma cells. J Neurochem 2006; 96: 766-776.
7. Kokkinakis DM, Bocangel DB, Schold SC, Moschel RC and Pegg AE. Thresholds of O6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroe-thyl)-1-nitrosourea or temozolomide. Clin Cancer Res 2001; 7: 421-428.
8. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC and Stupp R. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 2005; 352: 997-1003.
9. Kato T, Natsume A, Toda H, Iwamizu H, Sugita T, Hachisu R, Watanabe R, Yuki K, Motomura K, Bankiewicz K and Wakabayashi T. Efficient delivery of liposome-mediated MGMT-siRNA reinforces the cytotoxity of temozolomide in GBM-initiating cells. Gene Ther 2010; 17: 1363-1371.
10. White E, Bienemann A, Megraw L, Bunnun C and Gill S. Evaluation and optimization of the administration of a selectively replicating herpes simplex viral vector to the brain by convection-enhanced delivery. Cancer Gene Ther 2011; 18: 358-369.
11. White E, Bienemann A, Sena-Esteves M, Taylor H, Bunnun C, Castrique E and Gill S. Evaluation and optimization of the administration of recombinant adeno-associated viral vectors (serotypes 2/1, 2/2, 2/rh8, 2/9, and 2/rh10) by convection-enhanced delivery to the striatum. Hum Gene Ther 2011; 22: 237-251.
12. White E, Bienemann A, Malone J, Megraw L, Bunnun C, Wyatt M and Gill S. An evaluation of the relationships between catheter design and tissue mechanics in achieving high-flow convection-enhanced delivery. J Neurosci Methods 2011; 199: 87-97.
13. Iwami K, Natsume A and Wakabayashi T. Gene therapy for high-grade glioma. Neurol Med Chir (Tokyo) 2010; 50: 727-736.
14. Jackson AL, Bartz SR, Schelter J, Kobayashi SV, Burchard J, Mao M, Li B, Cavet G and Linsley PS. Expression profiling reveals off-target gene regulation by RNAi. Nat Biotechnol 2003; 21: 635-637.
15. Whitehead KA, Langer R and Anderson DG. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009; 8: 129-138.
16. Kikuchi A, Aoki Y, Sugaya S, Serikawa T, Takakuwa K, Tanaka K, Suzuki N and Kikuchi H. Development of novel cationic liposomes for efficient gene transfer into peritoneal disseminated tumor. Hum Gene Ther 1999; 10: 947-955.
17. Tachibana R, Harashima H, Ide N, Ukitsu S, Ohta Y, Suzuki N, Kikuchi H, Shinohara Y and Kiwada H. Quantitative analysis of correlation between number of nuclear plasmids and gene expression activity after transfection with cationic liposomes. Pharm Res 2002; 19: 377-381.
18. Sato Y, Murase K, Kato J, Kobune M, Sato T, Kawano Y, Takimoto R, Takada K, Miyanishi K, Matsunaga T, Takayama T and Niitsu Y. Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone. Nat Biotechnol 2008; 26: 431-442.
19. Rai K, Takigawa N, Ito S, Kashihara H, Ichihara E, Yasuda T, Shimizu K, Tanimoto M and Kiura K. Liposomal delivery of MicroRNA-7-expressing plasmid overcomes epidermal growth factor receptor tyrosine kinase inhibitor-resistance in lung cancer cells. Mol Cancer Ther 2011; 10: 1720-1727.
20. MacKay JA, Deen DF and Szoka FC Jr. Distribution in brain of liposomes after convection enhanced delivery; modulation by particle charge, particle diameter, and presence of steric coating. Brain Res 2005; 1035: 139-153.
21. Saito R, Krauze MT, Noble CO, Tamas M, Drummond DC, Kirpotin DB, Berger MS, Park JW and Bankiewicz KS. Tissue affinity of the infusate affects the distribution volume during convection-enhanced delivery into rodent brains: implications for local drug delivery. J Neurosci Methods 2006; 154: 225-232.
22. Miller AD. Lipid-based nanoparticles in cancer diagnosis and therapy. J Drug Deliv 2013; 2013: 165981.